{
    "clinical_study": {
        "@rank": "8156", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo pills to match valsartan tablets administered once daily"
            }, 
            {
                "arm_group_label": "valsartan 80mg daily", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "valsartan 160mg daily", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Dual chamber pacing is known to induce left ventricle remodeling and may eventually lead to\n      heart failure. The investigators aim to test hypothesis that valsartan started immediately\n      after dual chamber pacemaker implantation will prevent left ventricle remodeling in twelve\n      months long follow up in comparison with placebo. Echocardiographic assessment of left\n      ventricle remodeling will be correlated with plasma activity of matrix metalloproteinases\n      and their tissue inhibitors, indices of functional capacity such as plasma level of NTproBNP\n      and distance in meters during six minute walking test."
        }, 
        "brief_title": "Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "First Time Dual Chamber Pacemaker Implantation", 
        "condition_browse": {
            "mesh_term": "Ventricular Remodeling"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  informed written consent\n\n          -  age  \u2265 18 years\n\n          -  first time pacemaker implantation for trifascicular block, atrioventricular second or\n             third degree block\n\n          -  left ventricle ejection fraction  \u2265 40%\n\n        Exclusion Criteria:\n\n          -  significant valvular heart disease\n\n          -  ischaemic heart disease requiring further revascularization\n\n          -  symptomatic hypotension\n\n          -  orthostatic disorders\n\n          -  pregnancy, breast feeding, child bearing potential\n\n          -  previous use of angiotensin receptor blocking agents\n\n          -  known hypersensitivity to valsartan\n\n          -  significant liver disorders\n\n          -  significant renal disorders, including renal artery stenosis\n\n          -  hyperaldosteronism\n\n          -  chronic use of nonsteroid antiinflammatory drugs\n\n          -  chronic use of lithium salts\n\n          -  Patient's reluctance or disability to obey protocol and/or follow the scheduled\n             visits\n\n          -  any significant disease to reduce the expected life duration  < 12 months\n\n          -  participation in any other trial within the last 30 days before randomization\n\n          -  any situation that would put more risk on patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805804", 
            "org_study_id": "01/2012", 
            "secondary_id": "KNW-1-154/P/2/0"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo", 
                "valsartan 80mg daily", 
                "valsartan 160mg daily"
            ], 
            "intervention_name": "placebo/valsartan", 
            "intervention_type": "Drug", 
            "other_name": [
                "Valsartan", 
                "Other names:", 
                "Diovan", 
                "Axudan", 
                "Vanatex"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Valsartan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "dual chamber pacing, left ventricle remodeling, valsartan", 
        "lastchanged_date": "March 4, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zabrze", 
                        "country": "Poland", 
                        "state": "Upper Silesia", 
                        "zip": "41-800"
                    }, 
                    "name": "II Dept. of Cardiology in Zabrze Medical University of Silesia"
                }, 
                "investigator": [
                    {
                        "last_name": "Andrzej R Tomasik, MD PhD FESC", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Beata Bialkowska, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Wojciech Jachec, MD PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Celina Wojciechowska, MD PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Damian Kawecki, MD PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Grzegorz Kubiak, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Katarzyna Wozniak, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zbigniew Kalarus, MD PhD Professor", 
                    "phone": "0048323733682"
                }, 
                "facility": {
                    "address": {
                        "city": "Zabrze", 
                        "country": "Poland", 
                        "state": "Upper Silesia", 
                        "zip": "41-800"
                    }, 
                    "name": "Silesian Center for Heart Diseases"
                }, 
                "investigator": {
                    "last_name": "Zbigniew Kalarus, MD PhD Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ewa Birkner, Professor", 
                    "phone": "0048322722041"
                }, 
                "facility": {
                    "address": {
                        "city": "Zabrze", 
                        "country": "Poland", 
                        "state": "Upper Silesia", 
                        "zip": "41-800"
                    }, 
                    "name": "Dept. of Biochemistry Medical University of Silesia"
                }, 
                "investigator": {
                    "last_name": "Ewa Romuk, PhD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Artur Gabrysiak, MBA", 
                    "phone": "0048323732330"
                }, 
                "facility": {
                    "address": {
                        "city": "Zabrze", 
                        "country": "Poland", 
                        "state": "Upper Silesia", 
                        "zip": "41-800"
                    }, 
                    "name": "Medical Laboratory Dr med. Fryda"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Is There a Possibility to Pharmacologically Prevent Left Ventricle Remodeling in Patients With Pacemaker? Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker", 
        "overall_contact": {
            "email": "beata.bialkowska@sum.edu.pl", 
            "last_name": "Beata Bialkowska, MD", 
            "phone": "0048323732372"
        }, 
        "overall_official": {
            "affiliation": "Medical University of Silesia", 
            "last_name": "Ewa Nowalany-Kozielska, MD PhD Associate Professor", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Poland: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "change in echocardiographically  assessed left ventricle dimensions and left ventricle function", 
            "safety_issue": "No", 
            "time_frame": "baseline and 12 months"
        }, 
        "reference": [
            {
                "PMID": "19346662", 
                "citation": "Suzuki H, Geshi E, Nanjyo S, Nakano H, Yamazaki J, Sato N, Tanaka K, Takano T, Yagi H, Shibata T, Mochizuki S, Katagiri T. Inhibitory effect of valsartan against progression of left ventricular dysfunction after myocardial infarction: T-VENTURE study. Circ J. 2009 May;73(5):918-24. Epub 2009 Apr 2."
            }, 
            {
                "PMID": "20378999", 
                "citation": "Miyazaki S, Kasai T, Miyauchi K, Miyazaki T, Akimoto Y, Takagi A, Aihara K, Kawamura M, Suwa S, Kojima S, Sumiyoshi M, Daida H. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J. 2010 Jun;74(6):1158-64. Epub 2010 Apr 6."
            }, 
            {
                "PMID": "15486029", 
                "citation": "Garc\u00eda RA, Brown KL, Pavelec RS, Go KV, Covell JW, Villarreal FJ. Abnormal cardiac wall motion and early matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1080-7. Epub 2004 Oct 14."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805804"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Silesia", 
            "investigator_full_name": "Andrzej Tomasik MD PhD FESC", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in plasma level of matrix metalloproteinase 9", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }, 
            {
                "measure": "change in plasma level of NTproBNP", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }, 
            {
                "measure": "change in atrial arrhythmia burden assessed from pacemaker memory", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }, 
            {
                "measure": "change in the rate of occurrence of any major adverse cardiovascular event", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks, 3 months, 6 months, 9 months and 12 months"
            }, 
            {
                "measure": "change in plasma level of tissue necrosis factor alpha", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }, 
            {
                "measure": "change in plasma level of tissue inhibitor of matrix metalloproteinase 3", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }, 
            {
                "measure": "change in distance walked during six minute walking test", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 months"
            }
        ], 
        "source": "Medical University of Silesia", 
        "sponsors": {
            "collaborator": {
                "agency": "Polpharma Pharmaceutical Company", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Medical University of Silesia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}